Scientists at Oxford University have released more data that confirm coronavirus vaccines made by Pfizer-BioNTech and AstraZeneca both significantly cut the risk of infection after a single dose.
In studies published on Friday, researchers said there was no apparent difference in the vaccines' ability to reduce COVID-19 infection rates.
The research has not yet been published in a peer-reviewed journal but is based on data from nose and throat swabs taken from more than 370,000 participants in England and Wales between December and April.
The scientists said that three weeks after people had been given a single dose of either the Pfizer-BioNTech or AstraZeneca vaccine, the rates of all COVID-19 infections fell by 65 per cent. The reduction was bigger after a second dose and the vaccines appeared to protect people against the variant that was first identified in the UK.
Dr. Koen Pouwels, a senior researcher at Oxford University, noted there was some evidence of vaccinated people catching COVID-19 and that there was some limited spread of the disease from people who had been immunised.
This emphasises the need for everyone to continue to follow guidelines to reduce transmission risk, for example through social distancing and masks, Pouwels said in a statement.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)